LV 305

Drug Profile

LV 305

Alternative Names: Cancer vaccine DCVex NY-ESO-1 - Immune Design; DCVex™/NY-ESO-1 cancer vaccine - Immune Design; ID-LV305; LV 305

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Design
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Sarcoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease) in USA (Intradermal, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malignant-melanoma(Metastatic disease) in USA (Intradermal, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Metastatic disease) in USA (Intradermal, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top